Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bayer AG's quarterly accounts payable & accrued expense
declined
from Dec. 2025 (CHF7,974 Mil) to Mar. 2026 (CHF6,912 Mil) and
declined
from Mar. 2026 (CHF6,912 Mil) to Jun. 2026 (CHF6,869 Mil).
Bayer AG's annual accounts payable & accrued expense
declined
from Dec. 2023 (CHF8,483 Mil) to Dec. 2024 (CHF8,359 Mil) and
declined
from Dec. 2024 (CHF8,359 Mil) to Dec. 2025 (CHF7,974 Mil).
Bayer AG Accounts Payable & Accrued Expense Historical Data
* Premium members only.
The historical data trend for Bayer AG's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG Accounts Payable & Accrued Expense Calculation
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
What does a Accounts Payable & Accrued Expense of CHF6,869 Mil mean?
Bayer AG (XSWX:BAYN) has a Accounts Payable & Accrued Expense of CHF6,869 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Bayer AG and its competitors.
Is Bayer AG's Accounts Payable & Accrued Expense too high?
Bayer AG's current Accounts Payable & Accrued Expense is CHF6,869 Mil. Overall, Bayer AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Accounts Payable & Accrued Expense compare to LLY and JNJ?
Bayer AG's Accounts Payable & Accrued Expense of CHF6,869 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Bayer AG and its competitors. Bayer AG's current Accounts Payable & Accrued Expense is CHF6,869 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.56, compared to a current price of CHF45.85 — trading 86.7% above its estimated fair value. The current Accounts Payable & Accrued Expense is CHF6,869 Mil. Bayer AG's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Accounts Payable & Accrued Expense is CHF6,869 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF45.85 is trading 86.7% above its estimated GF Value™ of CHF24.56.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
Accounts Payable & Accrued Expense: CHF6,869 Mil
GF Value™: CHF24.56 vs. price of CHF45.85 (86.7% above fair value)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
51GF Score
Get the complete analysis for XSWX:BAYN
Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
